International immunopharmacology · 2026
Chlorogenic acid attenuates rheumatoid arthritis by modulating immunity via the gut microbiota-derived metabolite indolelactic acid.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Ling, Gao Haokun, Xue Guangjian, Pan Zhaoyi, Zhang Ran, Xie Minghui, Wang Na, Fan Jing, Liu Shujun, Zhang Huijiao, Zhang Shujuan, Geng Xianbo, Han Ke, Wu Nanping, Jin Changzhong
Аннотация
The pathogenesis of rheumatoid arthritis (RA) is closely associated with gut microbiota dysbiosis. Chlorogenic acid (CGA), a plant-derived polyphenol, exhibits well-documented anti-inflammatory and immunomodulatory activities; however, whether it alleviates RA through gut microbiota modulation remains unclear. In this study, a collagen-induced arthritis (CIA) mouse model was established, and we found that CGA significantly ameliorated arthritic symptoms and modulated systemic immune responses. 16S rRNA sequencing combined with antibiotic-mediated microbiota depletion confirmed that the anti-RA effect of CGA depended on an intact gut microbiota. Untargeted metabolomics further revealed that CGA treatment markedly enriched the gut microbiota-derived tryptophan metabolite indolelactic acid (ILA), whose levels correlated positively with the abundance of Lactobacillus. In vitro experiments demonstrated that ILA suppressed LPS-induced M1 polarization of RAW264.7 macrophages, downregulated the expression of pro-inflammatory cytokines such as IL-6 and TNF-α, and inhibited phosphorylation of NF-κB p65. Collectively, this study systematically elucidates the mechanism by which CGA alleviates RA via remodeling the gut microbiota, promoting ILA production, and subsequently inhibiting macrophage inflammatory polarization and modulating T-cell balance through the AhR/NF-κB signaling axis. These findings provide novel insights and potential therapeutic targets for RA treatment based on the "gut microbiota-metabolite-immune" axis.